Reduced FEV₁ as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors.

ABSTRACT:

Background

The aim of study is to investigate the influence of pulmonary function on the prognosis in patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI).

Patients and methods

Data were collected retrospectively from 151 patients with stage IV NSCLC who received ICI and completed spirometry before ICI therapy in Taipei Veterans General Hospital between January 2016 and December 2020. The co-primary end points were overall survival (OS) and progression-free survival (PFS) between groups divided by 80% predicted FEV₁ since ICI therapy started; the secondary outcomes were objective response rate.

Results

Among 151 patients enrolled to this study, 67.5% of patients were men, 75.5% were adenocarcinoma, 24.5% had

SUBMITTER: Shen YL 

PROVIDER: S-EPMC8980716 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature